Who are Pirfenidone Capsules（600mg）'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): WINREVAIR, Luspatercept Injectable Product, pirfenidone or nintedanib, Pirfenidone Capsules, SHR-A1904, Pirfenidone Oral Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pirfenidone-capsules-600mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pirfenidone Capsules（600mg） — Competitive Intelligence Brief

Pirfenidone Capsules（600mg） (Pirfenidone Capsules（600mg）) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrotic. Area: Respiratory.

phase 2 Antifibrotic TGF-β Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Pirfenidone Capsules（600mg） (Pirfenidone Capsules（600mg）) — Beijing Continent Pharmaceutical Co, Ltd.. Antifibrotic agent

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pirfenidone Capsules（600mg） TARGET	Pirfenidone Capsules（600mg）	Beijing Continent Pharmaceutical Co, Ltd.	phase 2	Antifibrotic	TGF-β
WINREVAIR	SOTATERCEPT-CSRK	MERCK SHARP DOHME	marketed		activin A and other TGF-β superfamily ligands
Luspatercept Injectable Product	Luspatercept Injectable Product	Sun Yat-sen University	marketed	Erythroid maturation agent	Activin A; TGF-β superfamily ligands
pirfenidone or nintedanib	pirfenidone or nintedanib	Hospices Civils de Lyon	marketed	Antifibrotic agent	Pirfenidone: TGF-β pathway; Nintedanib: FGFR, VEGFR, PDGFR tyrosine kinases
Pirfenidone Capsules	Pirfenidone Capsules	Shanghai Zhongshan Hospital	marketed	Antifibrotic agent	TGF-β pathway; multiple pro-fibrotic cytokines
SHR-A1904	SHR-A1904	Shanghai Hengrui Pharmaceutical Co., Ltd.	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β
Pirfenidone Oral Product	Pirfenidone Oral Product	Capital Medical University	phase 3	Antifibrotic	TGF-β receptor

Recent regulatory actions (last 90 days)

2026-03-25 — WINREVAIR · FDA · approved · US · MERCK SHARP DOHME

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrotic class)

Beijing Continent Pharmaceutical Co, Ltd. · 1 drug in this class
Capital Medical University · 1 drug in this class
Centro Dermatológico Dr. Ladislao de la Pascua · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pirfenidone Capsules（600mg） — Competitive Intelligence Brief. https://druglandscape.com/ci/pirfenidone-capsules-600mg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab